UroGen’s Zusduri benefit maintained in NMIBC Phase III study
Zusduri is the first non-surgical therapy to be approved for NMIBC, setting a new standard for the indication.
06 August 2025
06 August 2025
Zusduri is the first non-surgical therapy to be approved for NMIBC, setting a new standard for the indication.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.